Calydon announces issuance of two patents for technologies that destroy cancer tumors, including prostate cancer.Calydon, Inc. (Sunnyvale, CA; 408-734-0733) announced the issuance of two patents that expand its intellectual property in the area of engineering viruses to replicate in and kill prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. cells. United States Patent 5,871,726 claims a modified adenovirus adenovirus Any of a group of spheroidal viruses, made up of DNA wrapped in a protein coat, that cause sore throat and fever in humans, hepatitis in dogs, and several diseases in fowl, mice, cattle, pigs, and monkeys. that may be used as a therapeutic to introduce genetic constructs that are toxic to prostate cancer cells in a highly targeted and specific manner. Patent 5,830,686 claims a human prostate-specific transcriptional regulatory sequence regulatory sequence n. A DNA sequence responsible for regulating gene expression. , the polynucleotides that comprise such regions, the toxin gene that is controlled by the regulatory sequence, and methods for treating prostate disease using toxin gene constructs. United States Patent 5,871,726 and Patent 5,830,686 join Calydon's suite of viral therapeutics that target and treat prostate and other cancers. They include: United States Patent 5,648,478 that claims a human prostate tissue-specific enhancer gene, and methods that utilize the PSE PSE 1. pale soft exudative pork. 2. portosystemic encephalopathy. gene for treating prostate disease; United States Patent 5,698,443 that claims methods for constructing a virus that incorporates the human prostate tissue-specific enhancer gene for use in targeting and treating prostate cancer cells. United States Patent 5,783,435 claims methods and compositions for screening therapeutic agents for the treatment of prostate cancer. Calydon, a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , is engaged in the development of new therapeutics that target prostate and other cancers. The company is focused on the development of tissue-specific viruses that selectively destroy cancer cells. The company is conducting a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I for its prostate cancer therapeutic, CN706, at The Johns Hopkins Brady Urological Institute and The Johns Hopkins Oncology Center. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion